産品簡介:
Berberine
Chloride Hydrate 鹽酸小(xiǎo)檗堿水(shuǐ)合物(wù)（鹽酸黃連素水(shuǐ)合物(wù)）
産品信息
|
産品名稱
|
産品編号
|
規格
|
價格（元）
|
|
Berberine Chloride Hydrate 鹽酸小(xiǎo)檗堿水(shuǐ)合物(wù)（鹽酸黃連素水(shuǐ)合物(wù)）
|
MS2003-5G
|
5g
|
450
|
|
Berberine Chloride Hydrate 鹽酸小(xiǎo)檗堿水(shuǐ)合物(wù)（鹽酸黃連素水(shuǐ)合物(wù)）
|
MS2003-25G
|
25g
|
1380
|
産品描述
小(xiǎo)檗堿（Berberine）是來源于毛茛科藥用植物(wù)黃連的一(yī)種異喹啉類生(shēng)物(wù)堿，具有非常多(duō)樣的藥理作用，包括1）抗腫瘤效應，包括乳腺癌、白(bái)血病、黑(hēi)素瘤、鱗狀細胞癌、胰腺癌、肝癌等；2）一(yī)種有效的口服降血糖劑，對脂質代謝起到(dào)積極效果；3）一(yī)種中藥抗抑郁劑，一(yī)種阻止神經退行性紊亂的神經保護劑；4）減少非酒精性脂肪性肝病（NAFLD）大鼠的肝脂肪含量，也能(néng)防止肝星狀細胞（HSCs）增殖，HSCs在肝損傷中纖維化發展很關鍵；5）體外改善促炎症細胞因子誘導的腸道上(shàng)皮緊密連接損傷，可能(néng)是一(yī)種靶向診治藥物(wù)能(néng)夠複原腸道疾病狀态中的屏障功能(néng)；6）可能(néng)是一(yī)種廣譜的抗微生(shēng)物(wù)制劑；另外，小(xiǎo)檗堿在紫外光(guāng)照(zhào)下(xià)發熒光(guāng)，組織學研究中通(tōng)常用于肥大細胞顆粒内的肝素染色。
本品是鹽酸水(shuǐ)合物(wù)形式的小(xiǎo)檗堿，即鹽酸小(xiǎo)檗堿水(shuǐ)合物(wù)（Berberine
chloride hydrate or Berberine hydrochloride hydrate），又(yòu)稱為(wèi)鹽酸黃連素水(shuǐ)合物(wù)，CAS NO. 141433-60-5，以凍幹粉形式提供，純度＞98%。
産品特性
1） CAS NO：141433-60-5
2） 化學名：9,10-dimethoxy-5,6-dihydro-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-7-ium
chloride hydrate; 5,6- Dihydro-9,10-dimethoxybenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium
Chloride hydrate;
3） 同義名：Berberine
hydrochloride hydrate 鹽酸小(xiǎo)檗堿水(shuǐ)合物(wù)，氯化小(xiǎo)檗堿水(shuǐ)合物(wù)，鹽酸黃連素水(shuǐ)合物(wù)；黃連素鹽酸鹽水(shuǐ)合物(wù)；氯化黃連素水(shuǐ)合物(wù)；Natural Yellow 18 hydrate 自(zì)然黃18水(shuǐ)合物(wù)；
4） 分子式：C20H18ClNO4·xH2O
5）
分子量：371.81 (as
Anhydrous)
6）
純度：>98.0% (HPLC)
7）
含水(shuǐ)量：8-12%
8）
外觀：淺黃色至黃色結晶性粉末
9）
溶解性：溶于DMSO（5mg/ml），水(shuǐ)（＜4mg/ml，微熱助溶）
10）化學結構：
保存與運輸方法
保存：2-8ºC幹燥保存，或置于-20℃長(cháng)期保存，至少2年(nián)有效。
運輸：常溫運輸。
産品應用【來自(zì)文獻，僅做參考】
|
文獻1，Lee
YS et al.Berberine, a natural plant product,
activates AMP-activated protein kinase with beneficial metabolic effects in
diabetic and insulin-resistant states.Diabetes. 2006 Aug;55(8):2256-64. PMID: 16873688
體内研究：
實驗目的（Purpose）: Berberine has antidiabetic properties, although its
mode of action is unknown. Here, we have investigated the metabolic effects
of Berberine in two animal models of insulin resistance and in insulin- responsive
cell lines.
動物(wù)模型I（Animal Model I）：Obese and diabetic C57BLKS/J-Leprdb/Leprdbmale mice
實驗方法I（Assay I）：From 12
weeks of age, berberine was injected intraperitoneally (5 mg · kg body wt−1·
day−1) into the
mice for 26 days.
動物(wù)模型II（Animal Model II）：Wistar rats (250 g)were
acclimatized in communal cages at 22°C, with a 12-h light 12-h dark cycle
(lights on at 0600) for 1 week and had access to a standard chow diet and
water ad libitum. Rats
were then randomly assigned to receive either the standard chow diet as the
control group (CH group) or a high-fat (60% calories as saturated fat) diet
for 4 weeks.
實驗方法II（Assay II）：After 2 weeks of feeding, rats were randomly assigned to
receive oral administration of either vehicle (0.5% methylcellulose) or
berberine (380 mg · kg−1· day−1) by gavage
for the last 2 weeks.
|
|
文獻2，Zhu Y et al. Berberine induces apoptosis and DNA damage in
MG-63 human osteosarcoma cells.Mol Med Rep. 2014 Oct;10(4):1734-8. PMID:
25050485
體外研究：
實驗目的（Purpose）:To investigate the cytotoxic effect of berberine on
MG-63 cells
細胞類型（Cell type）：MG-63 human osteosarcoma cell line (wild type)
藥物(wù)配制（Preparation）：Berberine was dissolved in dimethyl sulfoxide (DMSO)
實驗方法（Assay）：MG-63 cells were seeded at a density of 1×104cells/well in 100 μl of cell culture medium and then placed in a 96-well plate.
Following 12 h of incubation, the cells were treated with 0, 20, 40, 80 μM
berberine for 12 and 24 h. MTT was used to detect cell cytotoxicity.
|
|
文獻3，Chu
SC et al.Berberine reverses
epithelial-to-mesenchymal transition and inhibits metastasis and
tumor-induced angiogenesis in human cervical cancer cells. Mol Pharmacol.
2014 Dec;86(6):609-23. PMID: 25217495
體内研究：
實驗目的（Purpose）:To study the in vivo antitumor effects of berberine
動物(wù)模型I（Animal Model I）：After subcutaneous implantation of SiHa cells, BALB/c nude
mice (n = 5 for each group) were treated with placebo or berberine and then
analyzed for tumor growth.
實驗方法I（Assay I）：The mice
were randomly divided into three groups (n = 5 for each group) and fed by
oral gavage with placebo (control) and berberine (10 and 20 mg/kg per day).
給藥途徑（Administration）：Oral gavage
|
注意事(shì)項
1）
本品并非商業(yè)化藥物(wù)，不可用作臨床或診斷用途，僅限科研使用。
2）
為(wèi)了您的安全和健康，請穿實驗服并戴一(yī)次性手套操作。
相(xiàng)關産品
|
産品名稱
|
産品編号
|
規格
|
價格（元）
|
|
Berberine 小(xiǎo)檗堿（黃連素）
|
MS2001-5MG
|
5mg
|
120
|
|
Berberine 小(xiǎo)檗堿（黃連素）
|
MS2001-20MG
|
20mg
|
400
|
|
Berberine
Chloride 鹽酸小(xiǎo)檗堿（鹽酸黃連素）
|
MS2002-20MG
|
20mg
|
220
|
|
Berberine
Chloride 鹽酸小(xiǎo)檗堿（鹽酸黃連素）
|
MS2002-100MG
|
100mg
|
600
|
|
Berberine
Chloride Hydrate 鹽酸小(xiǎo)檗堿水(shuǐ)合物(wù)（鹽酸黃連素水(shuǐ)合物(wù)）
|
MS2003-5G
|
5g
|
450
|
|
Berberine
Chloride Hydrate 鹽酸小(xiǎo)檗堿水(shuǐ)合物(wù)（鹽酸黃連素水(shuǐ)合物(wù)）
|
MS2003-25G
|
25g
|
1380
|
|
Berberine
Hydrogen Sulphate 硫酸小(xiǎo)檗堿（硫酸氫黃連素）
|
MS2004-20MG
|
20mg
|
300
|
|
Berberine
Hydrogen Sulphate 硫酸小(xiǎo)檗堿（硫酸氫黃連素）
|
MS2004-100MG
|
100mg
|
760
|
— —Written/Edited by V. Shallan【版權歸MKBio懋康所有】
上海夢澤生物科技有限公司是一(yī)家涉足于生(shēng)命科學和生(shēng)物(wù)技(jì)術(shù)領域研究的試劑、儀器(qì)和實驗室消耗品與實驗服務工(gōng)作，主要從(cóng)事(shì)細胞生(shēng)物(wù)學、植物(wù)學、分子生(shēng)物(wù)學、免疫學、生(shēng)物(wù)化學、蛋白(bái)組學。生(shēng)物(wù)制藥與診斷試劑研發生(shēng)産等領域。 本公司秉承“以人為(wèi)本，以誠為(wèi)信、合同守信”的經營理念。堅持"品質保障"的原則為(wèi)廣大客戶提供優質産品。
|
